美国甲状腺协会2026年孕前、妊娠及产后甲状腺疾病指南
美国甲状腺协会(ATA)发布2026年指南,更新孕前、妊娠及产后甲状腺疾病的诊疗推荐。指南基于系统文献检索和GRADE框架,涵盖甲状腺功能检测、碘补充、甲状腺自身免疫、甲减、甲亢、甲状腺结节与癌症及产后甲状腺功能障碍,为个体化患者护理提供优化框架。
要点
- 推荐涵盖孕前、妊娠及产后甲状腺功能检测、碘补充及甲状腺自身免疫管理。
- 针对甲减、甲亢、甲状腺结节与癌症及产后甲状腺功能障碍提供循证推荐。
- 指南承认多数证据质量低至中等,推荐基于当前最佳实践和国际专家共识。
核心结论
- 2026年ATA指南为孕前、妊娠及产后甲状腺疾病的诊断和管理提供了更新的循证推荐。
- 尽管多数证据仍为低至中等质量,指南代表了当前最佳实践和国际多学科专家的共识。
研究设计与样本
- 指南由ATA多学科工作组制定,包括10个国际学会代表、患者倡导组织代表及方法学家。
- 通过医学图书馆员支持的系统文献检索,采用GRADE框架评估证据并制定推荐。
关键数值与推荐
- 推荐涵盖甲状腺功能检测、碘补充、甲状腺自身免疫、甲减、低甲状腺素血症、甲亢与Graves病、甲状腺结节与癌症及产后甲状腺功能障碍。
- 推荐基于证据质量、利弊平衡、患者价值观、可行性和公平性制定,数据有限时形成良好实践声明。
临床怎么用
- 临床医生可依据指南对不孕女性、孕妇及产后/哺乳期女性进行甲状腺疾病的诊断和管理。
- 推荐以推荐表形式呈现,并附有实践考虑框和背景信息,便于个体化患者护理。
局限性
- 指南承认许多证据仍为低至中等质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thyroid disease in pregnancy, preconception, and postpartum is a common and clinically relevant problem. Since the publication of the American Thyroid Association (ATA) guidelines in 2017, substantial new clinical and scientific evidence has become available. The aim of these guidelines is to provide clinicians, patients, researchers, and policymakers with evidence-based recommendations on the care of women with thyroid disease before, during, and after pregnancy. METHODS: The clinical questions addressed were informed by prior ATA guidelines, stakeholder feedback, a global needs assessment, and input from the multidisciplinary task force. Systematic literature searches were conducted with the support from a medical librarian and evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation framework. Recommendations were formulated based on the quality of evidence, balance of benefits and harms, patient values, feasibility, and equity. Where data were limited, Good Practice Statements were formulated. The task force included representatives from 10 international societies as well as patient advocacy groups and a methodologist. RESULTS: The updated guidelines include recommendations on thyroid function testing, iodine supplementation, thyroid autoimmunity, hypothyroidism, hypothyroxinemia, hyperthyroidism and Graves' disease, thyroid nodules and cancer, and postpartum thyroid dysfunction for women with infertility, pregnant women, and women during postpartum and/or lactation. Recommendations are presented using recommendation tables, additional practical considerations are highlighted in boxes, and background information is provided in the text, tables, and figures per disease entity and chronological subset. CONCLUSIONS: These 2026 ATA guidelines provide updated, evidence-based recommendations for the diagnosis and management of thyroid disease in women during preconception, pregnancy, and postpartum. While acknowledging that much of the evidence remains of low-to-moderate quality, these guidelines represent current best practices and consensus among international experts from different fields, offering an optimized framework for individualized patient care.
引用
- Korevaar TIM, Leung AM, Alexander EK, et al. American Thyroid Association 2026 Guidelines for Thyroid Disease in Preconception, Pregnancy, and Postpartum. Thyroid. 2026. PMID: 42219800. doi:10.1177/10507256261445624
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。